Literature DB >> 22320918

Pathophysiology guided treatment of nonalcoholic steatohepatitis.

Tuyet A T Nguyen1, Arun J Sanyal.   

Abstract

Nonalcoholic fatty liver disease is a spectrum that ranges from benign steatosis to steatohepatitis. It has become the most common cause of chronic liver disease, and yet there continues to be a lack of effective therapeutic options. This article reviews current concepts underlying the pathophysiological basis of nonalcoholic steatohepatitis from development of insulin resistance to the establishment of fibrosis. Then using a physiology-based approach, specific targeted therapeutics are reviewed along with their drawbacks. The evidence behind current therapies is based predominantly on small trials and, thus, no recommendations can be made until larger randomized trials are conducted.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22320918      PMCID: PMC4900150          DOI: 10.1111/j.1440-1746.2011.07018.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  49 in total

1.  Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.

Authors:  Hideyuki Hyogo; Tadashi Ikegami; Katsutoshi Tokushige; Etsuko Hashimoto; Kazuo Inui; Yasushi Matsuzaki; Hironori Tokumo; Fumiaki Hino; Susumu Tazuma
Journal:  Hepatol Res       Date:  2011-09-22       Impact factor: 4.288

2.  Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.

Authors:  S L Samson; P Sathyanarayana; M Jogi; E V Gonzalez; A Gutierrez; R Krishnamurthy; R Muthupillai; L Chan; M Bajaj
Journal:  Diabetologia       Date:  2011-09-29       Impact factor: 10.122

3.  Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Authors:  Naga P Chalasani; Arun J Sanyal; Kris V Kowdley; Patricia R Robuck; Jay Hoofnagle; David E Kleiner; Aynur Unalp; James Tonascia
Journal:  Contemp Clin Trials       Date:  2008-09-10       Impact factor: 2.226

4.  Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.

Authors:  S Fiorucci; S Cipriani; A Mencarelli; F Baldelli; G Bifulco; A Zampella
Journal:  Mini Rev Med Chem       Date:  2011-08       Impact factor: 3.862

5.  Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.

Authors:  Claudia O Zein; Lisa M Yerian; Prema Gogate; Rocio Lopez; John P Kirwan; Ariel E Feldstein; Arthur J McCullough
Journal:  Hepatology       Date:  2011-08-24       Impact factor: 17.425

6.  Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

Authors:  Howard D Sesso; Julie E Buring; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Robert J Glynn; J Michael Gaziano
Journal:  JAMA       Date:  2008-11-09       Impact factor: 56.272

7.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

8.  Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Authors:  Luc F Van Gaal; André J Scheen; Aila M Rissanen; Stephan Rössner; Corinne Hanotin; Olivier Ziegler
Journal:  Eur Heart J       Date:  2008-04-15       Impact factor: 29.983

9.  Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.

Authors:  Manal F Abdelmalek; Schuyler O Sanderson; Paul Angulo; Consuelo Soldevila-Pico; Chen Liu; Joy Peter; Jill Keach; Matt Cave; Theresa Chen; Craig J McClain; Keith D Lindor
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

10.  The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study.

Authors:  Carmela Loguercio; Alessandro Federico; Marco Trappoliere; Concetta Tuccillo; Ilario de Sio; Agnese Di Leva; Marco Niosi; Mauro Valeriano D'Auria; Rita Capasso; Camillo Del Vecchio Blanco
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

View more
  8 in total

1.  Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.

Authors:  Zahid Ahmad; Lalitha Subramanyam; Lidia Szczepaniak; Vinaya Simha; Beverley Adams-Huet; Abhimanyu Garg
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

2.  Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy.

Authors:  Christopher P Neal; Christopher D Mann; Esme Pointen; Angus McGregor; Giuseppe Garcea; Matthew S Metcalfe; David P Berry; Ashley R Dennison
Journal:  J Gastrointest Surg       Date:  2012-08-25       Impact factor: 3.452

3.  Pathophysiology of NASH: perspectives for a targeted treatment.

Authors:  Fabio Marra; Sophie Lotersztajn
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

4.  Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units.

Authors:  Xiaona Hu; Yiqin Huang; Zhijun Bao; Yiqian Wang; Dongmei Shi; Fang Liu; Zhanjuan Gao; Xiaofeng Yu
Journal:  BMC Gastroenterol       Date:  2012-09-14       Impact factor: 3.067

Review 5.  Recent advances in understanding/management of non-alcoholic steatohepatitis.

Authors:  Tommy Pacana; Arun J Sanyal
Journal:  F1000Prime Rep       Date:  2015-03-03

6.  Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.

Authors:  Shu Dong; Zong-Ying Zhan; Hong-Yan Cao; Chao Wu; Yan-Qin Bian; Jian-Yuan Li; Gen-Hong Cheng; Ping Liu; Ming-Yu Sun
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

Review 7.  Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.

Authors:  Howard C Masuoka; Naga Chalasani
Journal:  Ann N Y Acad Sci       Date:  2013-01-30       Impact factor: 5.691

8.  Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci.

Authors:  Stefan Stender; Julia Kozlitina; Børge G Nordestgaard; Anne Tybjærg-Hansen; Helen H Hobbs; Jonathan C Cohen
Journal:  Nat Genet       Date:  2017-04-24       Impact factor: 38.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.